924287-64-9

Basic information

• Product Name: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester
• Synonyms: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester;2-Amino-4-fluoro-6-benzothiazolecarboxylic acid methyl ester
• CAS NO: 924287-64-9
• Molecular Formula: C₉H₇FN₂O₂S
• Molecular Weight: 226.2274832
• Mol File: 924287-64-9.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 390℃
• Flash Point: 190℃
• Appearance: /
• Density: 1.501
• CAS DataBase Reference: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester(924287-64-9)
• EPA Substance Registry System: 6-Benzothiazolecarboxylic acid, 2-aMino-4-fluoro-, Methyl ester(924287-64-9)

Safety Data

• Hazardous Substances Data: 924287-64-9(Hazardous Substances Data)

Usage

General Description

6-Benzothiazolecarboxylic acid, 2-amino-4-fluoro-, methyl ester is a chemical compound with the molecular formula C9H6FNO2S. It is an amino acid derivative that is often used in organic synthesis and pharmaceutical research. 6-Benzothiazolecarboxylic acid, 2-amino-4-fluoro-, methyl ester has potential applications in the development of new drugs and agrochemicals due to its interesting biological activities. However, it is important to handle this chemical with caution as it may have toxic or hazardous effects if not properly managed. Overall, 6-Benzothiazolecarboxylic acid, 2-amino-4-fluoro-, methyl ester is a versatile chemical with important implications in various scientific and industrial fields.

Upstream product

• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 540-72-7 sodium thiocyanide 
• 185629-32-7 methyl 4-amino-3-fluorobenzene carboxylate 
• 333-20-0 potassium thioacyanate 

Downstream Products

• 1383816-28-1 methyl-2-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorobenzo[d]thiazole-6-carboxylate 
• 1383816-29-2 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 
• 1383816-38-3 C₂₉H₂₆F₄N₄O₄S 
• 924287-65-0 methyl 2-bromo-4-fluoro-1,3-benzothiazole-6-carboxylate 

Relevant articles and documents

ANTIVIRAL HETEROCYCLIC COMPOUNDS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA

The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in humans and warm-blooded animals.

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.